Tempus AI, Inc. TEM recently announced the acquisition of Deep 6 AI, a leading artificial intelligence (AI) company ...

We recently published a list of 10 Best Performing Growth Stocks in 2025 In this article, we are going to take a look at ...

Researchers have discovered race-associated molecular differences in tumors that may impact the way patients with pancreatic ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Before the acquisition, Ambry served as Tempus' largest reference laboratory for hereditary cancer screening, and the companies had entered a strategic collaboration to provide a combined ...

Ataraxis AI, the leading AI precision medicine company, today announced its $20.4 million Series A financing led by AIX ...

Tempus AI (TEM) announced it has acquired Deep 6 AI. Deep 6 AI enables healthcare organizations to de-risk clinical trials, accelerate ...

This strategic move enhances Tempus AI's market position and service offerings by expanding its diagnostic capabilities, particularly in hereditary cancer screening and genetic testing for various ...

Tempus AI seeks to make medicine smarter. At its core, it collects and analyzes genetic and clinical data to help doctors make better treatment decisions, especially for cancer. They are trying to ...

Tempus AI, Inc. TEM recently announced the acquisition of Deep 6 AI, a leading artificial intelligence (AI) company specializing in clinical trial matching. This strategic move aims to enhance ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ ... which includes academic medical centers, National Cancer Institute (NCI)-Designated Cancer Centers, and NCI Community Oncology Research ...

Deep 6 is integrated with over 750 provider site locations spanning more than 30 million patients, which will materially add to Tempus’ existing ... National Cancer Institute (NCI)-Designated ...